Recent network meta-analyses identified the relative outcomes of various vitiligo monotherapies on vitiligo at 6 months.

Now, all eyes are set on the FDA-approved drug Ruxolitinib, manufactured by Incyte Pharmaceuticals, which is the first drug that can restore pigment in patients with nonsegmental vitiligo.

Lisa: I follow a vitiligo management plan developed with my dermatologist where I use Opzelura ® (ruxolitinib) cream 1.5%. I ...

In July 2022, ruxolitinib cream 1.5% received additional approval for the treatment of vitiligo, becoming the first therapy to receive FDA approval for repigmentation in this patient population.

Last year, Incyte became the first pharma company to get approval for a drug that can re-pigment the skin in vitiligo – topical JAK1/JAK2 inhibitor Opzelura (ruxolitinib) – for patients whose ...

Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the American Academy of Dermatology Annual Meeting.Ruxolitinib cream is a ...

non-segmental vitiligo with genital involvement, hidradenitis suppurativa, lichen planus, and lichen sclerosus. Two Phase III trials, TRuE-PN1 and TRuE-PN2, assessing ruxolitinib cream for prurigo ...

Medscape Medical News, April 27, 2023 Ruxolitinib for Vitiligo Approved for Marketing in EU Last year in the United States, the topical JAK inhibitor became the first repigmentation treatment ...

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first FDA ...